Clinical Trial Update: A Study of 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography in Heart Failure [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating 68Ga-FAPI PET imaging to assess fibroblast activation in heart failure with preserved ejection fraction is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction

Drugs mentioned

• 68Ga-FAPI (gallium-68 labeled fibroblast activation protein inhibitor)

Snippet

Sponsor: Mayo Clinic | Conditions: Heart Failure With Preserved Ejection Fraction | Phase 2 | Status: RECRUITING